All Phenotypes Tg(Vav1-cre)#Cgp MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Jak2^tm2.1Jlvl/Jak2⁺ Tg(Vav1-cre)#Cgp/0	involves: 129S2/SvPas * C57BL/6NTac	MGI:5538507
cn2	Mirc27^em1Hhzg/Mirc27^em1Hhzg Tg(Vav1-cre)#Cgp/0	involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj	MGI:7413041
cn3	Mirc30^em1Hhzg/Mirc30^em1Hhzg Tg(Vav1-cre)#Cgp/0	involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj	MGI:7413042
cn4	Bcr^{tm1(BCR/ABL)Tsr}/Bcr⁺ Runx1^tm3Dow/Runx1⁺ Tg(Vav1-cre)#Cgp/0	involves: C57BL/6	MGI:5525100
cn5	Bcr^{tm1(BCR/ABL)Tsr}/Bcr^{tm1(BCR/ABL)Tsr} Tg(Vav1-cre)#Cgp/0	involves: C57BL/6	MGI:5527191
cn6	Bcr^{tm1(BCR/ABL)Tsr}/Bcr⁺ Tg(Vav1-cre)#Cgp/0	involves: C57BL/6	MGI:5527200
cn7	Otud5^tm1Vmd/Otud5^tm1Vmd Tg(Vav1-cre)#Cgp/0	involves: C57BL/6	MGI:5896451
cn8	Phf6^em1Wencc/Y Tg(Vav1-cre)#Cgp/0	Not Specified	MGI:7280786
cn9	Phf6^em1Wencc/Phf6^em1Wencc Tg(Vav1-cre)#Cgp/0	Not Specified	MGI:7280785

Allelic Composition	Jak2^tm2.1Jlvl/Jak2⁺ Tg(Vav1-cre)#Cgp/0
Genetic Background	involves: 129S2/SvPas * C57BL/6NTac

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Jak2^tm2.1Jlvl mutation (0 available); any Jak2 mutation (59 available)
Tg(Vav1-cre)#Cgp mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

enlarged spleen ( J:202234 )

• mild at 6 weeks due to an increase in erythroblasts and myeloid cells

• severe at 12 weeks due to an increase in erythroblasts and myeloid cells

increased spleen weight ( J:202234 )

• 3-fold at 6 weeks

• 8-fold at 12 weeks

abnormal definitive hematopoiesis ( J:202234 )

abnormal myelopoiesis ( J:202234 )

• increased CFU-GM in the bone marrow, but not spleen

myeloid hyperplasia ( J:202234 )

• in the spleen

extramedullary hematopoiesis ( J:202234 )

• in the liver

decreased bone marrow cell number ( J:202234 )

increased erythroid progenitor cell number ( J:202234 )

• increased BFU-E in the spleen and bone marrow

• however, CFU-E numbers are normal in the bone marrow and spleen

decreased erythroblast number ( J:202234 )

• mature erythroblasts

increased erythrocyte cell number ( J:202234 )

• slightly at 2 weeks

• however, aged mice exhibit a drop in erythrocyte cell number to normal levels

increased hematocrit ( J:202234 )

• at 2 to 3 months and plateau for 5 months

• however, aged mice exhibit a drop in hematocrit to normal levels

increased hemoglobin content ( J:202234 )

• at 2 months and plateau for 4 months

• however, aged mice exhibit a drop in hemoglobin to normal levels

microcytosis ( J:202234 )

• severe

thrombocytosis ( J:202234 )

• severe, plateau for 6 months before decreasing in aged mice

decreased B cell number ( J:202234 )

increased leukocyte cell number ( J:202234 )

• early and more so in aged mice

increased granulocyte number ( J:202234 )

reticulocytosis ( J:202234 )

increased hematopoietic stem cell number ( J:202234 )

• at 3 months, mice exhibit increased LSK (2.3 times) and SLAM (2 time) cells in the bone marrow compared with control mice

• at 3 months, mice exhibit increased Lin- (1.5-fold), LSK (1.7-fold) and SLAM (3.7-fold) cells in the spleen compared with control mice

• 1, 3 and 6 month old mice exhibit a 3-, 4- and 5-fold increase, respectively, in total Lin- cells (bone marrow and spleen) compared with control mice

• at 3 months, mice exhibit a 3-fold and 7-fold increase in LSK and SLAM cells, respectively, compared with wild-type mice

• at 6 months, mice exhibit a 4-fold and 6-fold increase in LSK and SLAM cells, respectively, compared with wild-type mice

spleen fibrosis ( J:202234 )

• in aged mice

abnormal bone marrow cell physiology ( J:202234 )

• in transplantation experiments, bone marrow cells promotes hematopoietic cell proliferation compared to control cells

• however, IFNalpha treatment suppresses increased cell proliferation

skeleton

myelofibrosis ( J:202234 )

• in aged mice

immune system

enlarged spleen ( J:202234 )

• mild at 6 weeks due to an increase in erythroblasts and myeloid cells

• severe at 12 weeks due to an increase in erythroblasts and myeloid cells

increased spleen weight ( J:202234 )

• 3-fold at 6 weeks

• 8-fold at 12 weeks

abnormal myelopoiesis ( J:202234 )

• increased CFU-GM in the bone marrow, but not spleen

myeloid hyperplasia ( J:202234 )

• in the spleen

decreased B cell number ( J:202234 )

increased leukocyte cell number ( J:202234 )

• early and more so in aged mice

increased granulocyte number ( J:202234 )

spleen fibrosis ( J:202234 )

• in aged mice

growth/size/body

enlarged spleen ( J:202234 )

• mild at 6 weeks due to an increase in erythroblasts and myeloid cells

• severe at 12 weeks due to an increase in erythroblasts and myeloid cells

increased spleen weight ( J:202234 )

• 3-fold at 6 weeks

• 8-fold at 12 weeks

Allelic Composition	Mirc27^em1Hhzg/Mirc27^em1Hhzg Tg(Vav1-cre)#Cgp/0
Genetic Background	involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mirc27^em1Hhzg mutation (0 available); any Mirc27 mutation (3 available)
Tg(Vav1-cre)#Cgp mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

immune system phenotype ( J:320883 )

N	• mice exhibit normal blood and spleen CD5+ B cell numbers, spleen weight, NK cell development, early B-cell development, and immune cell homeostasis and function

neoplasm

neoplasm ( J:320883 )

N	• mice exhibit normal tumor development

Allelic Composition	Mirc30^em1Hhzg/Mirc30^em1Hhzg Tg(Vav1-cre)#Cgp/0
Genetic Background	involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mirc30^em1Hhzg mutation (0 available); any Mirc30 mutation (4 available)
Tg(Vav1-cre)#Cgp mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

increased spleen weight ( J:320883 )

increased pro-B cell number ( J:320883 )

• increased percentage

increased B cell number ( J:320883 )

• increased CD5+ B cell in the blood of 10-month-old mice

increased pre-B cell number ( J:320883 )

• increased percentage

abnormal NK cell morphology ( J:320883 )

• partially block NK cell development at the stage III to stage IV transition

neoplasm

increased chronic lymphocytic leukemia incidence ( J:320883 )

growth/size/body

increased spleen weight ( J:320883 )

hematopoietic system

increased spleen weight ( J:320883 )

increased pro-B cell number ( J:320883 )

• increased percentage

increased B cell number ( J:320883 )

• increased CD5+ B cell in the blood of 10-month-old mice

increased pre-B cell number ( J:320883 )

• increased percentage

abnormal NK cell morphology ( J:320883 )

• partially block NK cell development at the stage III to stage IV transition

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
chronic lymphocytic leukemia		DOID:1040	OMIM:109543 OMIM:151400 OMIM:609630 OMIM:612557 OMIM:612558 OMIM:612559	J:320883

Allelic Composition	Bcr^{tm1(BCR/ABL)Tsr}/Bcr⁺ Runx1^tm3Dow/Runx1⁺ Tg(Vav1-cre)#Cgp/0
Genetic Background	involves: C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcr^{tm1(BCR/ABL)Tsr} mutation (1 available); any Bcr mutation (51 available)
Runx1^tm3Dow mutation (0 available); any Runx1 mutation (34 available)
Tg(Vav1-cre)#Cgp mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:203111 )

• 50% of mice die between 6-12 months of age

hematopoietic system

increased neutrophil cell number ( J:203111 )

• prior to death mice exhibit neutrophilia and/or moncytosis

thrombocytopenia ( J:203111 )

• prior to death mice exhibit thrombocytopenia

decreased lymphocyte cell number ( J:203111 )

• prior to death mice exhibit lymphopenia

increased monocyte cell number ( J:203111 )

• prior to death mice exhibit neutrophilia and/or moncytosis

immune system

increased neutrophil cell number ( J:203111 )

• prior to death mice exhibit neutrophilia and/or moncytosis

decreased lymphocyte cell number ( J:203111 )

• prior to death mice exhibit lymphopenia

increased monocyte cell number ( J:203111 )

• prior to death mice exhibit neutrophilia and/or moncytosis

Allelic Composition	Bcr^{tm1(BCR/ABL)Tsr}/Bcr^{tm1(BCR/ABL)Tsr} Tg(Vav1-cre)#Cgp/0
Genetic Background	involves: C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcr^{tm1(BCR/ABL)Tsr} mutation (1 available); any Bcr mutation (51 available)
Tg(Vav1-cre)#Cgp mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

normal phenotype

no abnormal phenotype detected ( J:203111 )

• mice remained disease free throughout observation period (10-12 months)

Allelic Composition	Bcr^{tm1(BCR/ABL)Tsr}/Bcr⁺ Tg(Vav1-cre)#Cgp/0
Genetic Background	involves: C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcr^{tm1(BCR/ABL)Tsr} mutation (1 available); any Bcr mutation (51 available)
Tg(Vav1-cre)#Cgp mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

abnormal bone marrow cell physiology ( J:203111 )

• bone marrow cells from mutant mice exhibit an engraftment advantage when cotransplanted into lethally irradiated mice with wild type bone marrow cells

Allelic Composition	Otud5^tm1Vmd/Otud5^tm1Vmd Tg(Vav1-cre)#Cgp/0
Genetic Background	involves: C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Otud5^tm1Vmd mutation (0 available); any Otud5 mutation (9 available)
Tg(Vav1-cre)#Cgp mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

abnormal T-helper 17 cell differentiation ( J:219495 )

• increased IL17+ type 3 innate lymphoid cells

hematopoietic system

abnormal T-helper 17 cell differentiation ( J:219495 )

• increased IL17+ type 3 innate lymphoid cells

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

cellular

increased hematopoietic stem cell proliferation ( J:278804 )

• reduced number of type 2 and 3 multi-potent progenitor cells (MMP2s, MPP3s), LSK and long-term hematopoietic stem cells (LT-HSCs) in G0 cell cycle phase in bone marrow at age 8-12 weeks

endocrine/exocrine glands

abnormal thymus cell ratio ( J:278804 )

• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks

growth/size/body

enlarged spleen ( J:278804 )

• at age 18 months

• normal spleen weight and histology at age 8-12 weeks

hematopoietic system

hematopoietic system phenotype ( J:278804 )

N	• normal white blood cell count (WBC) at age 8 weeks

increased hematopoietic stem cell proliferation ( J:278804 )

• reduced number of type 2 and 3 multi-potent progenitor cells (MMP2s, MPP3s), LSK and long-term hematopoietic stem cells (LT-HSCs) in G0 cell cycle phase in bone marrow at age 8-12 weeks

abnormal thymus cell ratio ( J:278804 )

• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks

enlarged spleen ( J:278804 )

• at age 18 months

• normal spleen weight and histology at age 8-12 weeks

increased pro-B cell number ( J:278804 )

• in bone marrow at age 8-12 weeks

extramedullary hematopoiesis ( J:278804 )

• in spleen red pulp at age 18 months

decreased bone marrow cell number ( J:278804 )

• reduced number of LK and Lin- cells at age 8-12 weeks

increased bone marrow cell number ( J:278804 )

• increased number of type 2 multi-potent progenitor cells (MPP2s) at age 8-12 weeks

decreased granulocyte monocyte progenitor cell number ( J:278804 )

• in bone marrow at age 8-12 weeks

abnormal megakaryocyte morphology ( J:278804 )

• hyper- and dysplastic, smaller and with hypolobulated nuclei in bone marrow at age 18 months

increased megakaryocyte cell number ( J:278804 )

• hyperplastic in bone marrow at age 18 months

thrombocytopenia ( J:278804 )

• in blood at age 18 months

increased B cell number ( J:278804 )

• more B220+ cells at ages 8-12 weeks and 18 months

• normal percentage of B cells in spleen at age 8-12 weeks

increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number ( J:278804 )

• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells in spleen at age 8-12 weeks

abnormal effector T cell number ( J:278804 )

• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen at age 8-12 weeks

decreased lymphocyte cell number ( J:278804 )

• in blood at age 18 months

decreased double-negative T cell number ( J:278804 )

• reduced in thymus at age 8-12 weeks

decreased CD4-positive, alpha-beta T cell number ( J:278804 )

• at age 8-12 weeks and in spleen at age 18 months

• normal percentage in spleen at age 8-12 weeks

decreased CD8-positive, alpha-beta T cell number ( J:278804 )

• at age 8-12 weeks and in spleen at age 18 months

• reduced percentage in spleen at age 8-12 weeks

decreased hematopoietic stem cell number ( J:278804 )

• reduced number of long-term hematopoietic stem cells (LT-HSCs) in bone marrow at age 18 months

increased hematopoietic stem cell number ( J:278804 )

• in bone marrow at age 8-12 weeks

abnormal splenic cell ratio ( J:278804 )

• reduced percentage of T cells at age 8-12 weeks

• reduced percentage of CD8+ T cells at ages 8-12 weeks and 18 months

• increased percentage of CD4+ T cells at age 18 months

• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells at ages 8-12 weeks and 18 months

• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen ages 8-12 weeks and 18 months

• normal percentage of CD4+ T cells at age 8-12 weeks

• normal percentage of B cells at age 8-12 weeks

immune system

immune system phenotype ( J:278804 )

• normal spleen and thymus weight and histology at age 8-12 weeks

• normal percentage of B cells in spleen at age 8-12 weeks

• normal total, naive regulatory and effector T cell function in cytokine stimulation assays at age 8-12 weeks

• normal number of B cells in bone marrow other than pro-B cells at age 8-12 weeks

• normal number of long-term hematopoietic stem cells (LT-HSCs) in bone marrow at age 8-12 weeks

abnormal thymus cell ratio ( J:278804 )

• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks

enlarged spleen ( J:278804 )

• at age 18 months

• normal spleen weight and histology at age 8-12 weeks

increased pro-B cell number ( J:278804 )

• in bone marrow at age 8-12 weeks

increased B cell number ( J:278804 )

• more B220+ cells at ages 8-12 weeks and 18 months

• normal percentage of B cells in spleen at age 8-12 weeks

increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number ( J:278804 )

• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells in spleen at age 8-12 weeks

abnormal effector T cell number ( J:278804 )

• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen at age 8-12 weeks

decreased lymphocyte cell number ( J:278804 )

• in blood at age 18 months

decreased double-negative T cell number ( J:278804 )

• reduced in thymus at age 8-12 weeks

decreased CD4-positive, alpha-beta T cell number ( J:278804 )

• at age 8-12 weeks and in spleen at age 18 months

• normal percentage in spleen at age 8-12 weeks

decreased CD8-positive, alpha-beta T cell number ( J:278804 )

• at age 8-12 weeks and in spleen at age 18 months

• reduced percentage in spleen at age 8-12 weeks

abnormal splenic cell ratio ( J:278804 )

• reduced percentage of T cells at age 8-12 weeks

• reduced percentage of CD8+ T cells at ages 8-12 weeks and 18 months

• increased percentage of CD4+ T cells at age 18 months

• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells at ages 8-12 weeks and 18 months

• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen ages 8-12 weeks and 18 months

• normal percentage of CD4+ T cells at age 8-12 weeks

• normal percentage of B cells at age 8-12 weeks

skeleton

skeleton phenotype ( J:278804 )

N	• normal bone marrow cellularity and architecture at ages 8-12 weeks and 18 months

Allelic Composition	Phf6^em1Wencc/Phf6^em1Wencc Tg(Vav1-cre)#Cgp/0
Genetic Background	Not Specified

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Phf6^em1Wencc mutation (0 available); any Phf6 mutation (12 available)
Tg(Vav1-cre)#Cgp mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

immune system phenotype ( J:278804 )

• normal spleen and thymus weight and histology at age 8-12 weeks

• normal percentage of B cells in spleen at age 8-12 weeks

• normal total, naive regulatory and effector T cell function in cytokine stimulation assays at age 8-12 weeks

• normal number of B cells in bone marrow other than pro-B cells at age 8-12 weeks

• normal number of long-term hematopoietic stem cells (LT-HSCs) in bone marrow at age 8-12 weeks

abnormal thymus cell ratio ( J:278804 )

• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks

enlarged spleen ( J:278804 )

• at age 18 months

• normal spleen weight and histology at age 8-12 weeks

increased pro-B cell number ( J:278804 )

• in bone marrow at age 8-12 weeks

abnormal effector T cell number ( J:278804 )

• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen at age 8-12 weeks

decreased lymphocyte cell number ( J:278804 )

• in blood at age 18 months

decreased double-negative T cell number ( J:278804 )

• reduced in thymus at age 8-12 weeks

decreased CD4-positive, alpha-beta T cell number ( J:278804 )

• at age 8-12 weeks

• normal percentage in spleen at age 8-12 weeks

decreased CD8-positive, alpha-beta T cell number ( J:278804 )

• at age 8-12 weeks

• reduced percentage in spleen at age 8-12 weeks

increased leukocyte cell number ( J:278804 )

• at age 8 weeks

increased B cell number ( J:278804 )

• more B220+ cells at ages 8-12 weeks and 18 months

• normal percentage of B cells in spleen at age 8-12 weeks

increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number ( J:278804 )

• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells in spleen at age 8-12 weeks

abnormal splenic cell ratio ( J:278804 )

• reduced percentage of T cells at age 8-12 weeks

• reduced percentage of CD8+ T cells at ages 8-12 weeks and 18 months

• increased percentage of CD4+ T cells at age 18 months

• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells at ages 8-12 weeks and 18 months

• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen ages 8-12 weeks and 18 months

• normal percentage of CD4+ T cells at age 8-12 weeks

• normal percentage of B cells at age 8-12 weeks

hematopoietic system

increased hematopoietic stem cell proliferation ( J:278804 )

• reduced number of type 2 and 3 multi-potent progenitor cells (MMP2s, MPP3s), LSK and long-term hematopoietic stem cells (LT-HSCs) in G0 cell cycle phase in bone marrow at age 8-12 weeks

abnormal thymus cell ratio ( J:278804 )

• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks

enlarged spleen ( J:278804 )

• at age 18 months

• normal spleen weight and histology at age 8-12 weeks

increased pro-B cell number ( J:278804 )

• in bone marrow at age 8-12 weeks

extramedullary hematopoiesis ( J:278804 )

• in spleen red pulp at age 18 months

decreased bone marrow cell number ( J:278804 )

• reduced number of LK and Lin- cells at age 8-12 weeks

increased bone marrow cell number ( J:278804 )

• increased number of type 2 multi-potent progenitor cells (MPP2s) at age 8-12 weeks

decreased granulocyte monocyte progenitor cell number ( J:278804 )

• in bone marrow at age 8-12 weeks

abnormal megakaryocyte morphology ( J:278804 )

• hyper- and dysplastic, smaller and with hypolobulated nuclei in bone marrow at age 18 months

increased megakaryocyte cell number ( J:278804 )

• hyperplastic in bone marrow at age 18 months

thrombocytopenia ( J:278804 )

• in blood at age 18 months

abnormal effector T cell number ( J:278804 )

• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen at age 8-12 weeks

decreased lymphocyte cell number ( J:278804 )

• in blood at age 18 months

decreased double-negative T cell number ( J:278804 )

• reduced in thymus at age 8-12 weeks

decreased CD4-positive, alpha-beta T cell number ( J:278804 )

• at age 8-12 weeks

• normal percentage in spleen at age 8-12 weeks

decreased CD8-positive, alpha-beta T cell number ( J:278804 )

• at age 8-12 weeks

• reduced percentage in spleen at age 8-12 weeks

increased leukocyte cell number ( J:278804 )

• at age 8 weeks

increased B cell number ( J:278804 )

• more B220+ cells at ages 8-12 weeks and 18 months

• normal percentage of B cells in spleen at age 8-12 weeks

increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number ( J:278804 )

• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells in spleen at age 8-12 weeks

decreased hematopoietic stem cell number ( J:278804 )

• reduced number of long-term hematopoietic stem cells (LT-HSCs) in bone marrow at age 18 months

increased hematopoietic stem cell number ( J:278804 )

• in bone marrow at age 8-12 weeks

abnormal splenic cell ratio ( J:278804 )

• reduced percentage of T cells at age 8-12 weeks

• reduced percentage of CD8+ T cells at ages 8-12 weeks and 18 months

• increased percentage of CD4+ T cells at age 18 months

• increased percentage of naive regulatory (B220- TCRB+ CD4+ CD8- CD25+) T cells at ages 8-12 weeks and 18 months

• reduced percentage of effector (B220- TCRB+ CD4+ CD8- CD25-) T cells in spleen ages 8-12 weeks and 18 months

• normal percentage of CD4+ T cells at age 8-12 weeks

• normal percentage of B cells at age 8-12 weeks

endocrine/exocrine glands

abnormal thymus cell ratio ( J:278804 )

• reduced CD4- CD8- double-negative T cell numbers at age 8-12 weeks

growth/size/body

enlarged spleen ( J:278804 )

• at age 18 months

• normal spleen weight and histology at age 8-12 weeks

cellular

increased hematopoietic stem cell proliferation ( J:278804 )

• reduced number of type 2 and 3 multi-potent progenitor cells (MMP2s, MPP3s), LSK and long-term hematopoietic stem cells (LT-HSCs) in G0 cell cycle phase in bone marrow at age 8-12 weeks

skeleton

skeleton phenotype ( J:278804 )

N	• normal bone marrow cellularity and architecture at ages 8-12 weeks and 18 months

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 10/29/2024 MGI 6.24